Welcome to Paid Research Studies




  • Condition:   Hematopoietic Cell Transplantation
    Interventions:   Biological: Quadrivalent Inactivated Influenza Vaccine;   Other: Laboratory Biomarker Analysis;   Biological: Trivalent Influenza Vaccine
    Sponsor:   Vanderbilt-Ingram Cancer Center
    Not yet recruiting - verified June 2017

  • Conditions:   Sickle Cell Disease;   Kidney Injury;   Kidney Diseases;   Kidney Disease, Chronic
    Intervention:  
    Sponsors:   University of Alabama at Birmingham;   Pfizer
    Recruiting - verified April 2017

  • Condition:   Cytomegalovirus (CMV)
    Interventions:   Drug: Maribavir;   Drug: Valganciclovir;   Drug: Placebo
    Sponsor:   Shire
    Recruiting - verified July 2017

  • Conditions:   Blastoid Variant Mantle Cell Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Follicular Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Mantle Cell Lymphoma
    Interventions:   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2017

  • Conditions:   Non-small Cell Lung Cancer (NSCLC);   Lung Metastasis
    Interventions:   Drug: Porfimer sodium;   Device: Fiber optic
    Sponsor:   Concordia Laboratories Inc.
    Recruiting - verified June 2017

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Daratumumab
    Sponsor:   Janssen Research & Development, LLC
    Recruiting - verified July 2017

  • Conditions:   B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Ph-Like Acute Lymphoblastic Leukemia;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Condition:   Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
    Interventions:   Device: NovoTTF-100M device;   Other: Best Standard of Care
    Sponsor:   NovoCure Ltd.
    Recruiting - verified July 2017

  • Conditions:   Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Dermoid Cyst;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Acute Leukemia of Ambiguous Lineage;   Childhood B Acute Lymphoblastic Leukemia;   KMT2A Gene Rearrangement;   Mixed Phenotype Acute Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2017

  • Conditions:   Childhood Brain Stem Neoplasm;   Childhood Lymphoma;   Childhood Solid Neoplasm;   Pineal Region Neoplasm;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Visual Pathway Glioma;   Refractory Central Nervous System Neoplasm
    Interventions:   Drug: Entinostat;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Hematologic Malignancies;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Chronic Myelogenous Leukemia
    Interventions:   Biological: ProTmune;   Biological: Control Arm
    Sponsor:   Fate Therapeutics
    Recruiting - verified June 2017

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PD-L1 antibody;   Drug: Daratumumab;   Drug: Lenalidomide;   Drug: Pomalidomide
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified June 2017

  • Condition:   Degenerative Disc Disease
    Interventions:   Drug: rexlemestrocel-L;   Drug: rexlemestrocel-L + HA;   Drug: Placebo
    Sponsors:   Mesoblast, Ltd.;   Quintiles, Inc.
    Recruiting - verified May 2017

  • Condition:   Metastatic Breast Cancer
    Interventions:   Drug: paclitaxel;   Drug: Reparixin;   Drug: placebo
    Sponsors:   Dompé Farmaceutici S.p.A;   PRA Health Sciences
    Recruiting - verified May 2017

  • Conditions:   Heart Attack;   NSTEMI
    Interventions:   Biological: AMI MultiStem cells;   Other: Sham
    Sponsors:   Athersys, Inc;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified November 2016

  • Conditions:   Metastatic Ewing Sarcoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Bone Marrow;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Biological: Ganitumab;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Surgical Procedure;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Hematologic Neoplasms;   Graft-Versus-Host Disease
    Intervention:   Device: Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
    Sponsor:   Ayman Saad
    Recruiting - verified December 2016

  • Condition:   Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (NMO/NMOSD)
    Interventions:   Biological: MEDI-551;   Other: Placebo
    Sponsor:   MedImmune LLC
    Recruiting - verified May 2017

  • Conditions:   Adult Fibrosarcoma;   Alveolar Soft Part Sarcoma;   Angiomatoid Fibrous Histiocytoma;   Atypical Fibroxanthoma;   Clear Cell Sarcoma of Soft Tissue;   Epithelioid Malignant Peripheral Nerve Sheath Tumor;   Epithelioid Sarcoma;   Extraskeletal Myxoid Chondrosarcoma;   Extraskeletal Osteosarcoma;   Fibrohistiocytic Neoplasm;   Glomus Tumor of the Skin;   Inflammatory Myofibroblastic Tumor;   Intimal Sarcoma;   Leiomyosarcoma;   Liposarcoma;   Low Grade Fibromyxoid Sarcoma;   Low Grade Myofibroblastic Sarcoma;   Malignant Cutaneous Granular Cell Tumor;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Triton Tumor;   Mesenchymal Chondrosarcoma;   Myxofibrosarcoma;   Myxoid Chondrosarcoma;   Myxoinflammatory Fibroblastic Sarcoma;   Nerve Sheath Neoplasm;   PEComa;   Pericytic Neoplasm;   Plexiform Fibrohistiocytic Tumor;   Sclerosing Epithelioid Fibrosarcoma;   Stage IB Soft Tissue Sarcoma;   Stage IIB Soft Tissue Sarcoma;   Stage III Soft Tissue Sarcoma;   Stage IV Soft Tissue Sarcoma;   Synovial Sarcoma;   Undifferentiated (Embryonal) Sarcoma;   Undifferentiated High Grade Pleomorphic Sarcoma of Bone
    Interventions:   Drug: Doxorubicin Hydrochloride;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   B Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   Philadelphia Chromosome Positive;   Recurrent Adult Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Biological: Blinatumomab;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Prednisone;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Condition:   Granulomatous Disease, Chronic
    Intervention:  
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Primary Immune Deficiency Treatment Consortium;   Rare Diseases Clinical Research Network;   Pediatric Blood and Marrow Transplant Consortium
    Recruiting - verified September 2016

  • Condition:   Wiskott-Aldrich Syndrome
    Intervention:  
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Primary Immune Deficiency Treatment Consortium;   Rare Diseases Clinical Research Network
    Recruiting - verified September 2016

  • Condition:   Chronic Heart Failure
    Interventions:   Biological: Allogeneic Mesenchymal Precursor Cells (MPC);   Other: Sham Comparator
    Sponsor:   Mesoblast, Inc.
    Recruiting - verified October 2016

  • Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Severe Aplastic Anemia;   Allogeneic Transplant
    Intervention:   Drug: Cyclophosphamide
    Sponsor:   University of Alabama at Birmingham
    Recruiting - verified October 2016

  • Condition:   Adult Lymphoblastic Lymphoma
    Interventions:   Drug: Fludarabine;   Procedure: Total Body Irradiation
    Sponsor:   University of Alabama at Birmingham
    Recruiting - verified December 2016

  • Conditions:   Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer;   Colon Cancer;   Rectal Cancer;   GIST;   Anal Cancer;   Bile Duct Cancer;   Duodenal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Liver Cancer;   Small Intestine Cancer;   Peritoneal Surface Malignancies;   Familial Adenomatous Polyposis;   Lynch Syndrome;   Bladder Cancer;   Kidney Cancer;   Penile Cancer;   Prostate Cancer;   Testicular Cancer;   Ureter Cancer;   Urethral Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer;   Lip Cancer;   Oral Cavity Cancer;   Nasopharyngeal Cancer;   Oropharyngeal Cancer;   Paranasal Sinus Cancer;   Nasal Cavity Cancer;   Salivary Gland Cancer;   Skin Cancer;   CNS Tumor;   CNS Cancer;   Mesothelioma;   Breastcancer;   Leukemia;   Melanoma;   Sarcoma;   Unknown Primary Tumor;   Multiple Myeloma;   Ovarian Cancer;   Endometrial Cancer;   Vaginal Cancer
    Intervention:  
    Sponsor:   University of Nebraska
    Recruiting - verified May 2017

  • Conditions:   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   BCR/ABL1 Fusion Protein Negative;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Condition:   Infusion Reactions
    Intervention:   Biological: unlicensed CBU
    Sponsor:   New York Blood Center
    Recruiting - verified April 2017

  • Conditions:   Down Syndrome;   Fetal Aneuploidy
    Intervention:  
    Sponsor:   Sequenom, Inc.
    Recruiting - verified October 2016

  • Conditions:   Hematologic Malignancies;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Platelets;   Histiocytic Disorders;   Acute Myelogenous Leukemia (AML or ANLL);   Acute Lymphoblastic Leukemia (ALL);   Other Acute Leukemia;   Chronic Myelogenous Leukemia (CML);   Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases;   Other Leukemia;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma;   Multiple Myeloma/ Plasma Cell Disorder (PCD);   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Disorders of the Immune System;   Automimmune Diseases;   Severe Aplastic Anemia
    Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
    Recruiting - verified July 2017

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone;   Procedure: Autologous Stem Cell Transplant
    Sponsors:   Paul G. Richardson, MD;   Celgene Corporation;   Millennium Pharmaceuticals, Inc.;   Massachusetts General Hospital;   Cape Cod Healthcare;   Beth Israel Deaconess Medical Center;   Emory University;   University of Michigan;   Fox Chase Cancer Center;   Memorial Sloan Kettering Cancer Center;   Fred Hutchinson Cancer Research Center;   Barbara Ann Karmanos Cancer Institute;   Duke University;   University of California, San Francisco;   University of Chicago;   M.D. Anderson Cancer Center;   UNC Lineberger Comprehensive Cancer Center;   Roswell Park Cancer Institute;   Stanford University;   University of Mississippi Medical Center;   Icahn School of Medicine at Mount Sinai;   Wake Forest University Health Sciences;   University of Arizona;   OHSU Knight Cancer Institute;   Eastern Maine Medical Center;   University of California, San Diego;   University of Alabama at Birmingham;   University of Pittsburgh;   Ochsner Health System;   University of Texas Southwestern Medical Center;   State University of New York - Downstate Medical Center;   Newton-Wellesley Hospital;   Baylor College of Medicine;   City of Hope Medical Center;   University of Florida;   Northwell Health;   H. Lee Moffitt Cancer Center and Research Institute;   Vanderbilt University Medical Center;   Ohio State University;   Huntsman Cancer Institute;   Columbia University
    Recruiting - verified January 2017

  • Condition:   Hematopoietic Stem Cell Transplantation
    Intervention:   Device: CD3+ T cell depletion
    Sponsors:   Ayman Saad;   Miltenyi Biotec, Inc.
    Recruiting - verified December 2016

  • Condition:   Cancer
    Interventions:   Genetic: DNA analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2016

  • Conditions:   Clear Cell Sarcoma of the Kidney;   Congenital Mesoblastic Nephroma;   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Rhabdoid Tumor of the Kidney;   Stage I Renal Cell Cancer;   Stage I Wilms Tumor;   Stage II Renal Cell Cancer;   Stage II Wilms Tumor;   Stage III Renal Cell Cancer;   Stage III Wilms Tumor;   Stage IV Renal Cell Cancer;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
    Interventions:   Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2016